4D Molecular Therapeutics
FDMT
63 hedge funds and large institutions have $515M invested in 4D Molecular Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 11 reducing their positions, and 4 closing their positions.
191% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 11
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
29% more capital invested
Capital invested by funds: $400M → $515M (+$115M)
13% more funds holding
Funds holding: 56 → 63 (+7)
8.89% more ownership
Funds ownership: 62.1% → 71% (+8.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.6M |
| 3 |
CC
Centiva Capital
New York
|
+$10.2M |
| 4 |
JP Morgan Chase
New York
|
+$6.18M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.61M |
| 2 |
Morgan Stanley
New York
|
-$1.78M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$901K |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$754K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$531K |
FDMT Hedge Fund Activity: Q3 2021 in Review
63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2021, worth a combined $515M — up 29% from $400M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new FDMT positions and 4 closed out — a net gain of 7 holders — while 32 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $20.2M. The largest seller was Millennium Management, cutting an estimated $5.61M.
- 63 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2021, up from 56 in Q2 2021.
- Funds reported $515M of 4D Molecular Therapeutics stock for Q3 2021, up 29% quarter-over-quarter.
- 11 funds opened new 4D Molecular Therapeutics positions in Q3 2021 and 4 closed out, a net change of +7 holders.
- The largest 4D Molecular Therapeutics buyer in Q3 2021 was BlackRock, an estimated $20.2M added.
- The largest 4D Molecular Therapeutics seller in Q3 2021 was Millennium Management, an estimated $5.61M sold.
Based on aggregated 13F filings for Q3 2021.